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Introduction {#bjs5100-sec-0008}
============

Colorectal cancer is one of the most common malignancies worldwide, accounting for at least one million new cancer cases each year[1](#bjs5100-bib-0001){ref-type="ref"}. Spread to the liver occurs commonly, with roughly one‐third of patients developing distant metastases[2](#bjs5100-bib-0002){ref-type="ref"} [3](#bjs5100-bib-0003){ref-type="ref"}. Although surgical therapy for patients with resectable colorectal liver metastases (CRLMs) offers a 20 per cent possibility of cure 6--7 years after resection, many will not achieve long‐term benefit[3](#bjs5100-bib-0003){ref-type="ref"} [4](#bjs5100-bib-0004){ref-type="ref"}. As the indications for liver‐directed therapies broaden, the ability to identify patients likely to benefit from intervention is important. Several morphological factors, such as number and size of metastases, carcinoembryonic antigen (CEA) level and the interval between primary tumour and the recognition of hepatic metastases, have been shown to be useful in predicting outcome[5](#bjs5100-bib-0005){ref-type="ref"}.

The potential aggressiveness of colorectal cancer is readily evident when relapses occur early after resection of the primary tumour, when it recurs in the liver with large or bilobar metastases, and when there is little or no measurable response to chemotherapy. Indicators of tumour biology and how they might influence outcome are of increasing interest. Mutation of the *KRAS* gene may be an indicator of biological aggressiveness[6](#bjs5100-bib-0006){ref-type="ref"}, [7](#bjs5100-bib-0007){ref-type="ref"}, [8](#bjs5100-bib-0008){ref-type="ref"}. The relationship between the growth rate of CRLMs and biological features of colorectal cancer may provide additional information related to outcome.

The aim of the present study was to estimate CRLM growth rate by assessing tumour doubling time in a consecutive series of patients with metachronous liver disease who had undergone liver resection. Although assessment of tumour growth rate requires at least two observations of volumes, it is difficult to justify this for every patient in a clinical setting. A mathematical approach was adopted to overcome this problem to validate and investigate the relationship of doubling time with clinical features and outcomes after liver resection.

Methods {#bjs5100-sec-0009}
=======

The study was approved by the Institutional Review Boards and ethical committees of all participating centres.

Between January 2001 and July 2013, consecutive patients undergoing liver resection for CRLMs with no extrahepatic disease were identified from prospectively developed databases at four Italian tertiary referral hospitals for inclusion in the present analysis. Patients with incomplete data, who had undergone preoperative portal vein embolization, or in whom a two‐stage hepatectomy had been adopted were excluded. Patients presenting with synchronous CRLMs were also excluded, retaining those with metachronous disease. In this group, those with no history of receiving chemotherapy in the interval between primary colorectal cancer surgery and CRLM resection were used for initial doubling time estimation.

Patients were deemed to have technically resectable disease when the metastases could be resected completely and the future remnant liver volume was considered adequate. Demographics, clinical data and CRLM features were collected for each patient. The resection margin was defined as R0Par when it was greater than 1 mm and as R1Vasc when the CRLM was detached from a major vessel structure. Both were considered curative, as suggested recently[9](#bjs5100-bib-0009){ref-type="ref"} [10](#bjs5100-bib-0010){ref-type="ref"}. Otherwise, the resection margin was defined as R1Par. Primary tumour characteristics, time from resection of the primary tumour to liver resection and the adoption of chemotherapy (either adjuvant after primary colonic surgery or neoadjuvant before liver resection) were also detailed. When available, the mutational status of *KRAS*, determined on the primary colorectal cancer, was recorded. The chemotherapy strategy was prescribed by the oncologist in charge. Irinotecan, oxaliplatin, capecitabine and monoclonal antibodies were offered to patients after their approval by the Italian national healthcare system. Follow‐up included clinical examination, estimation of serum CEA level, and CT or MRI at 3, 6 or every 12 months, as determined by the oncologist and clinical circumstances. Follow‐up was carried out by assessing the clinical records of the respective institutions or by telephone contact with the referring clinician or patient.

Growth evaluation {#bjs5100-sec-0010}
-----------------

The solution proposed relied in the concept of the genesis of liver metastases from the deposition of undetected/microscopic colorectal cancer tumour spheroids that initiate CRLM macroscopic growth. On this basis, the following mathematical solution was adopted.

Patients with no history of chemotherapy in the interval between primary colorectal cancer surgery and CRLM resection were considered initially. The formula developed by Schwartz, doubling time = *t ×* ln2/(ln(*V* ~2~) − ln(*V* ~1~)), was applied for estimation of doubling time, where *t* is the time interval between measurements, and *V* ~2~ and *V* ~1~ are the tumour volumes at the end and beginning of the time interval[11](#bjs5100-bib-0011){ref-type="ref"} [12](#bjs5100-bib-0012){ref-type="ref"}. *V* ~2~ was defined as the largest CRLM diameter in the resected specimen. *V* ~1~ was obtained by assuming that aggregates of colorectal cancer cells had already settled in the liver at the time of primary tumour surgery, but were as yet undetectable. A plausible range of CRLM sizes that would exist before macroscopic diagnosis at the time of colonic resection was assumed. Research suggested that *V* ~1~ could be calculated from a starting size of a tumour spheroid of 200 μm in radius, and a maximum diameter of 6 mm was taken on the basis that this represented the lower limit for CRLM identification by common imaging techniques[13](#bjs5100-bib-0013){ref-type="ref"} [14](#bjs5100-bib-0014){ref-type="ref"}.

Between the two *V* ~1~ extremes (from 200 μm to 6 mm), a triangular distribution of *V* ~1~ was assumed as the best approximation when the real distribution was unknown[15](#bjs5100-bib-0015){ref-type="ref"}. Ten different random *V* ~1~ values within the applied range were simulated. The variable *t* was calculated as the time between primary colorectal cancer surgery, where undetectable tumour aggregates were assumed to be already present, and the time of liver resection, at which point the tumour size provided the *V* ~2~ estimate. Doubling time was calculated for each of the ten simulated values of *V* ~1~, maintaining the value of *t* fixed as defined above. The average doubling time value over the ten simulations was used as the main outcome measure.

To provide plausibility and confirmation of the mathematical approach, obtained doubling time values were compared with available published data. A systematic search of PubMed and Institute for Scientific Information (ISI) Web of Knowledge databases was performed for articles published to 1 February 2018 relevant to the tumour doubling time assessment of CRLM. The PubMed database was searched using the following keywords: 'doubling time'\[All Fields\] OR 'growth rate'\[All Fields\] AND (colorectal\[All Fields\] AND ('liver'\[MeSH Terms\] AND/OR ('neoplasm metastasis'\[MeSH Terms\] OR ('neoplasm'\[All Fields\] AND 'metastasis'\[All Fields\]) OR 'neoplasm metastasis'\[All Fields\] OR 'metastases'\[All Fields\])). ISI Web of Knowledge was searched using the following terms: ((TS='doubling time' OR TS='growth rate') AND (TS='colorectal' AND TS='metastases')) AND document types: (Article). The search was limited to human subjects and language limitations were imposed. The reference list of identified studies was also searched manually until no additional eligible trials could be identified. Additional articles were searched in Google Scholar without retrieving any additional available study.

Statistical analysis {#bjs5100-sec-0011}
--------------------

The Mann--Whitney test was used to compare doubling time as the distribution was not normal. Natural logarithm conversion of doubling time was used in univariable and multivariable regression models. A nomogram to predict doubling time was generated using coefficients from the multivariable model through the least common denominator approach. Overall survival (OS) was calculated with the Kaplan--Meier method using the log rank test from the date of liver resection until the last follow‐up visit (censored) or death. Recurrence‐free survival (RFS) was calculated considering intrahepatic, extrahepatic or both types of metastasis as the event and censoring the last follow‐up visit and deaths. The hazard rate (HR) of these survival measures was explored by applying the Kernel‐smoothed estimator with Epanechnikov function[16](#bjs5100-bib-0016){ref-type="ref"} [17](#bjs5100-bib-0017){ref-type="ref"}. This analytical technique for lifetime data is flexible, model‐free and data‐driven, so that no shape assumption is imposed other than that of hazard function as a smooth function over time[18](#bjs5100-bib-0018){ref-type="ref"}. For OS and RFS over the entire study population, the Kernel‐smoothed hazard estimator was initially unadjusted for possible confounding factors, whereas when analysing the relationship between doubling time and RFS, the estimator was adjusted at the mean of other co‐variables found able to modify prognosis[17](#bjs5100-bib-0017){ref-type="ref"}. Tumour doubling time data retrieved from literature were pooled using the random‐effects model of DerSimonian and Laird. Statistical analyses were done using STATA^®^ software (StataCorp, College Station, Texas, USA). *P* \< 0·050 (two‐tailed) was considered statistically significant.

Results {#bjs5100-sec-0012}
=======

Of 1063 patients undergoing liver resection for CRLMs without extrahepatic disease who were identified originally, 97 were excluded because of incomplete data, preoperative portal vein embolization or a two‐stage hepatectomy. A further 605 had synchronous CRLMs, leaving 361 patients who had undergone resection for metachronous disease including 149 with no history of chemotherapy in the interval between primary colorectal cancer surgery and CRLM resection. These patients were used for initial doubling time estimation, the remaining 212 patients being considered afterwards.

Baseline characteristics of the study population are shown in *Table*  [1](#bjs5100-tbl-0001){ref-type="table"}. The mean doubling time value in the 149 patients was 71·4 (95 per cent c.i. 62·8 to 79·9) days. Based on the literature search, 69 abstracts were screened. Of these, 61 abstracts were considered not pertinent and eight full texts were reviewed. Five studies[19](#bjs5100-bib-0019){ref-type="ref"}, [20](#bjs5100-bib-0020){ref-type="ref"}, [21](#bjs5100-bib-0021){ref-type="ref"}, [22](#bjs5100-bib-0022){ref-type="ref"}, [23](#bjs5100-bib-0023){ref-type="ref"} were finally considered eligible for inclusion, reporting doubling time for 181 patients with CRLMs. The pooled mean doubling time was 73·7 (95 per cent c.i. 43·9 to 103·5) days. The distributions of doubling time values for patients without and with chemotherapy are depicted in *Fig*. [1](#bjs5100-fig-0001){ref-type="fig"}.

###### 

Characteristics of patients with metachronous colorectal liver metastases

                                                                   No. of patients (*n* = 361)
  --------------------------------------------------------------- -----------------------------
  Age (years)[\*](#bjs5100-note-0003){ref-type="fn"}                       68 (60--74)
  Age ≥ 70 years                                                           152 (42·1)
  Sex ratio (M : F)                                                         246 : 115
  Primary tumour location                                         
  Right colon                                                              136 (37·7)
  Left colon                                                               137 (40·0)
  Rectum                                                                    88 (24·4)
  Primary tumour T category                                       
  T1                                                                        12 (3·3)
  T2                                                                        49 (13·6)
  T3                                                                       253 (70·1)
  T4                                                                        47 (13·0)
  Primary tumour N category                                       
  N0                                                                       156 (43·2)
  N1                                                                       131 (36·3)
  N2                                                                        74 (20·5)
  AJCC tumour stage (7th edition)                                 
  I                                                                         37 (10·2)
  II                                                                       119 (33·0)
  III                                                                      205 (56·8)
  Primary tumour *KRAS* status                                    
  Wild‐type                                                                 63 (17·5)
  Mutant                                                                    59 (16·3)
  n.d.                                                                     239 (66·2)
  Chemotherapy between surgery for CRC and CRLM                            212 (58·7)
  Disease‐free interval ≥ 24 months                                        207 (57·3)
  Largest CRLM size (cm)[\*](#bjs5100-note-0003){ref-type="fn"}          3·0 (2·0--4·5)
  No. of CRLMs[\*](#bjs5100-note-0003){ref-type="fn"}                       2 (1--3)
  R0 resection[†](#bjs5100-note-0004){ref-type="fn"}                       309 (85·6)
  Extension of hepatectomy                                        
  Single or multiple wedges                                                160 (44·3)
  Segmentectomy ± wedges                                                    42 (11·6)
  Bisegmentectomy ± wedges                                                  58 (16·1)
  Major hepatectomy ± wedges                                               101 (28·0)
  Adjuvant chemotherapy after liver resection                           226 of 329 (68·7)

Values in parentheses are percentages unless indicated otherwise;

values are median (i.q.r.).

Includes 17 patients with R1Vasc resection margin. n.d., Not determined; CRC, colorectal cancer; CRLM, colorectal liver metastasis.

![Distribution of doubling time values estimated in patients without and with chemotherapy. The mean doubling time in patients with no chemotherapy between colorectal cancer surgery and metastasis resection was of 71·4 (95 per cent c.i. 62·8 to 79·9) days and that in patients receiving chemotherapy was 78·0 (71·4 to 84·8) days. Corresponding median values are reported in *Table*  [2](#bjs5100-tbl-0002){ref-type="table"}](BJS5-3-186-g001){#bjs5100-fig-0001}

The relationships between doubling time estimation and features of the primary tumour and CRLMs are reported in *Table*  [2](#bjs5100-tbl-0002){ref-type="table"}. In univariable analyses, doubling time was significantly shorter in patients with right‐sided colorectal cancer, more advanced tumour stage, mutant *KRAS*, and in those who did not receive chemotherapy between primary colonic surgery and CRLM resection. Multivariable analysis confirmed stage, *KRAS* status and chemotherapy as independent predictors of doubling time (*Fig*. [2](#bjs5100-fig-0002){ref-type="fig"}).

###### 

Univariable regression analysis of primary colorectal cancer features in relation to estimated doubling time

                                                   Doubling time (days)[\*](#bjs5100-note-0006){ref-type="fn"}    Regression results   
  ----------------------------------------------- ------------------------------------------------------------- ---------------------- -------
  Age (years)                                                                                                                          
  \< 70                                                                 63·6 (44·3--95·4)                          1·00 (reference)    
  ≥ 70                                                                  56·4 (31·1--93·3)                        −0·09 (−0·22, 0·04)    0·184
  Sex                                                                                                                                  
  F                                                                     61·3 (37·6--94·1)                          1·00 (reference)    
  M                                                                     63·1 (41·3--94·7)                         0·05 (−0·10, 0·19)    0·526
  CRC location                                                                                                                         
  Right colon                                                           57·0 (35·4--88·9)                          1·00 (reference)    
  Left colon                                                            66·7 (39·8--93·4)                         0·15 (0·00, 0·29)     0·044
  Rectum                                                                67·8 (40·4--97·1)                         0·12 (−0·06, 0·30)    0·189
  Primary CRC T category                                                                                                               
  T1                                                                   125·9 (65·2--154·8)                         1·00 (reference)    
  T2                                                                   65·2 (45·6--103·6)                        −0·54 (−0·85, −0·23)   0·001
  T3                                                                    61·7 (38·3--94·0)                        −0·61 (−0·89, −0·32)   0·001
  T4                                                                    52·4 (31·9--72·0)                        −0·79 (−1·11, −0·48)   0·001
  Primary CRC nodal status                                                                                                             
  N0                                                                   65·2 (44·2--103·3)                          1·00 (reference)    
  N1                                                                    64·3 (39·9--93·5)                        −0·04 (−0·18, 0·10)    0·579
  N2                                                                    52·8 (31·4--82·4)                        −0·28 (−0·46, −0·09)   0·003
  AJCC tumour stage (7th edition)                                                                                                      
  I                                                                    72·5 (52·7--122·2)                          1·00 (reference)    
  II                                                                    61·3 (39·6--91·6)                        −0·27 (−0·51, 0·04)    0·024
  III                                                                   60·2 (37·2--95·6)                        −0·34 (−0·54, −0·13)   0·001
  *KRAS* primary CRC                                                                                                                   
  Wild‐type                                                            70·8 (40·2--122·7)                          1·00 (reference)    
  n.d.                                                                  63·0 (44·1--95·6)                        −0·11 (−0·29, 0·08)    0·247
  Mutant                                                                49·5 (28·3--88·5)                        −0·33 (−0·58, −0·14)   0·001
  No. of CRLMs                                                                                                                         
  1                                                                    68·4 (44·2--103·6)                          1·00 (reference)    
  2--3                                                                  58·1 (39·2--91·8)                        −0·05 (−0·19, 0·09)    0·448
  \> 3                                                                  52·4 (33·6--82·0)                        −0·15 (−0·32, 0·02)    0·079
  Chemotherapy between surgery for CRC and CRLM                                                                                        
  Yes                                                                  65·6 (45·0--100·9)                          1·00 (reference)    
  No                                                                    52·1 (35·9--94·7)                        −0·14 (−0·25, −0·03)   0·013

Values in parentheses are 95 per cent confidence intervals unless indicated otherwise;

values are median (i.q.r.).

Coefficients relate to logistic transformation of doubling time. Time from primary colonic resection and colorectal liver metastasis (CRLM) size were not analysed as they are already included in the calculation of doubling time. n.d., Not determined; CRC, colorectal cancer.

![Nomogram of the relationships between primary colorectal cancer features and estimated colorectal liver metastasis doubling times. Slow, intermediate and fast growth were based on the following tertiles for doubling time: fast, less than 48 days (120 patients); intermediate, 48--82 days (120 patients); slow, more than 82 days (121 patients). The score was obtained through the least common denominator of regression coefficients. Coefficients were as follows: T2, −0·53 (95 per cent c.i. −0·83 to −0·24; *P* = 0·001); T3, −0·56 (−0·83 to −0·29; *P* = 0·001); T4, −0·71 (−0·988 to −0·42; *P* = 0·001); N2, −0·14 (−0·29 to −0·99; *P* = 0·042); *KRAS* undetermined, −0·06 (−0·25 to 0·13; *P* = 0·519); *KRAS* mutant, −0·32 (−0·57 to −0·07; *P* = 0·013); no chemotherapy, −0·17 (−0·30 to −0·04; *P* = 0·010). WT, wild‐type](BJS5-3-186-g002){#bjs5100-fig-0002}

For the subsequent survival analyses, doubling times were divided into tertiles as follows: fast‐growing CRLMs, doubling time less than 48 days (120 patients); intermediate‐growing CRLMs, doubling time 48--82 days (120 patients); slow‐growing CRLMs, doubling time more than 82 days (121 patients).

Survival analyses after resection of colorectal liver metastases {#bjs5100-sec-0013}
----------------------------------------------------------------

Within a median follow‐up of 70·8 months after liver resection, 243 (67·3 per cent) of the 361 patients developed recurrence and 184 died (51·0 per cent). Of patients with recurrence, 151 had intrahepatic recurrences (97 confined to the liver, 54 both intrahepatic and extrahepatic). Median overall survival for the entire cohort was 49·1 months, and 1‐, 3‐ and 5‐year OS rates were 91·2, 58·8 and 45·0 per cent respectively. Median RFS was 17·2 months, and 1‐, 3‐ and 5‐year RFS rates were 62·8, 32·2 and 28·0 per cent respectively. RFS was significantly reduced by shorter doubling time (*P* \< 0·001), higher number of CRLMs (*P* = 0·002), lack of posthepatectomy chemotherapy (*P* = 0·002) and positive resection margins (*P* = 0·006).

HRs over time for recurrence and death are plotted in *Fig*. [3](#bjs5100-fig-0003){ref-type="fig"}. The HR for recurrence was greatest (approximately 3·8 per cent per month) between months 9 and 16 after surgery. The rate then started to decrease, becoming lower than the risk of death from the 36th month onwards. By contrast, the HR for death was greatest (about 1·8 per cent per month) between the 20th and 28th month after surgery, and subsequently decreased.

![Kernel‐smoothed estimates of hazard rates over time for death and recurrence](BJS5-3-186-g003){#bjs5100-fig-0003}

Adjusted results on HRs for recurrence by doubling time are depicted in *Fig*. [4](#bjs5100-fig-0004){ref-type="fig"} *a*. Fast‐growing tumours had the maximum risk of recurrence (approximately 7 per cent per month) between the ninth and 12th month after surgery. The risk of recurrence then slowly decreased until the 18th month, and then rapidly diminished. Intermediate‐growing tumours showed a similar temporal course, but with a monthly risk somewhat lower (about 4 per cent per month). In contrast, slow‐growing tumours showed their maximum risk of recurrence (about 3·3 per cent per month) later in the postoperative period. After the second year from surgery onwards, the HR for recurrence was similar in these three groups.

![Kernel‐smoothed estimates of hazard rates for **a** recurrence and **b** death in relation to colorectal liver metastasis doubling time: fast growth, less than 48 days (120 patients); intermediate growth, 48--82 days (120 patients); slow growth, more than 82 days (121 patients)](BJS5-3-186-g004){#bjs5100-fig-0004}

The HR for death of fast‐growing CRLMs was greatest (about 2·7 per cent per month) between the 16th and 22nd month after surgery, with another increase (around 2·0 per cent per month) between the 29th and 39th month. The HR for death then fell to the rates found for intermediate‐ and slow‐growing tumours (*Fig*. [4](#bjs5100-fig-0004){ref-type="fig"} *b*).

All adjusted HRs for recurrence in relation to features found during and after hepatectomy are reported in *Table*  [3](#bjs5100-tbl-0003){ref-type="table"}. The presence of more than three CRLMs resulted in a monthly HR greater than that that of less advanced CRLMs in the first 2 years after surgery. Positive resection margins led to a consistently higher HR over time compared with the HR for negative resection margins. The positive impact of postoperative chemotherapy was confined to the first 6 months after operation.

###### 

Kernel‐smoothed estimator of the monthly hazard rate of development of tumour recurrence after colorectal cancer liver metastasis resection in relation to characteristics at liver surgery and postoperative time interval

                                     Estimate of monthly hazard rate (%)[\*](#bjs5100-note-0008){ref-type="fn"}                                    
  --------------------------------- ---------------------------------------------------------------------------- ---------------- ---------------- ----------------
  CRLM doubling time                                                                                                                               
  Slow growth                                                      2·1 (1·8--2·5)                                 3·0 (2·7--3·2)   3·3 (3·0--3·4)   2·2 (1·7--2·9)
  Intermediate growth                                              3·1 (2·8--3·5)                                 3·8 (3·6--3·9)   2·8 (2·5--3·5)   2·2 (1·8--2·5)
  Fast growth                                                      4·9 (4·0--5·9)                                 7·0 (6·6--7·2)   5·4 (3·1--6·7)   1·9 (1·4--2·5)
  No. of CRLMs                                                                                                                                     
  1                                                                3·3 (3·1--3·8)                                 4·5 (4·0--4·7)   3·5 (2·6--4·4)   2·3 (2·0--2·5)
  2--3                                                             3·2 (3·0--3·4)                                 3·9 (3·7--4·0)   3·2 (2·8--3·8)   1·8 (1·0--2·6)
  \> 3                                                             4·5 (4·3--4·7)                                 5·1 (4·8--5·3)   5·6 (5·0--5·9)   2·8 (0·8--4·7)
  Resection margin                                                                                                                                 
  R0Par/R1Vasc                                                     3·2 (2·9--3·5)                                 4·1 (3·8--4·3)   3·4 (2·6--4·0)   1·8 (1·5--2·5)
  R1Par                                                            5·0 (4·6--5·4)                                 5·8 (5·6--6·0)   5·1 (4·5--5·9)   4·8 (4·2--5·3)
  Chemotherapy after CRLM surgery                                                                                                                  
  Yes                                                              2·8 (2·4--3·3)                                 4·3 (3·7--4·6)   3·7 (2·9--4·4)   1·9 (1·4--2·7)
  No                                                               5·8 (5·6--6·0)                                 5·4 (4·5--6·1)   3·4 (2·9--4·2)   2·4 (2·2--2·6)

Values are mean (range). Each estimate was adjusted for the remaining variables. Slow, intermediate and fast growth of colorectal liver metastases (CRLMs) were based on the following identified tertiles for doubling time: fast, less than 48 days (120 patients); intermediate, 48--82 days (120 patients); slow, more than 82 days (121 patients). R0Par, resection margin greater than 1 mm; R1Vasc, CRLM detached from major vessel structure; R1Par, resection margin 1 mm or less.

Discussion {#bjs5100-sec-0014}
==========

The development of CRLMs, recurrence after liver resection and life expectancy depend on the complex interaction between the primary colorectal cancer, treatments and patient response.

In this study a significant relationship between doubling time in the primary tumour and CRLM growth rate was observed. The fact that T status, N category and *KRAS* mutational status accounted for different CRLM doubling times relies on the 'seed and soil' concept in stochastic and deterministic ways[24](#bjs5100-bib-0024){ref-type="ref"} [25](#bjs5100-bib-0025){ref-type="ref"}. From a stochastic point of view, circulating tumour cells from the primary colorectal cancer are already present in the liver at the time of primary surgery, or might extravasate from the bloodstream at a second or different time point. In both cases they can either form macrometastases or remain dormant, often for a long period of time[24](#bjs5100-bib-0024){ref-type="ref"} [26](#bjs5100-bib-0026){ref-type="ref"}, [27](#bjs5100-bib-0027){ref-type="ref"}, [28](#bjs5100-bib-0028){ref-type="ref"}. The initial colorectal cancer stages may involve the dissemination of solitary and rare cell aggregates that cannot proceed to macroscopic tumour development, resulting in long doubling times (for example, T1 of 125·9 days). Conversely, more advanced colorectal cancer stages could determine the release of more tumour cell aggregates to seed the liver, with higher probabilities that one (or more) of them will grow into clinically detectable macrometastases, resulting in shorter doubling times (for example, T4 of 52·4 days).

The deterministic point of view is based on the fact that neoplasms contain genetically diverse tumour cell subpopulations (genetic heterogeneity), each with a different metastatic potential. In the initial stages of colorectal cancer, genetic subpopulations with low metastatic potential may be less capable of progressing to macrometastases. On the other hand, advanced colorectal cancers may be more likely to give rise to macrometastases because further genetic changes have appeared. The present findings support this process. In fact, CRLMs from mutant *KRAS* tumours grew faster than those derived from wild‐type colorectal cancers. The *KRAS* mutation has been associated with an increased rate of primary colorectal cancer vascular invasion and decreased expression of regulatory mechanisms, which result in faster proliferation, and an increased rate of haematogenous spread[29](#bjs5100-bib-0029){ref-type="ref"}, [30](#bjs5100-bib-0030){ref-type="ref"}, [31](#bjs5100-bib-0031){ref-type="ref"}.

The complex interaction between tumour biology, treatments and patient responses after liver resection was evident in the variability of the monthly hazard of recurrence and death in different subgroups. Fast‐growing tumours showed a peak in the HR for recurrence within the first year after surgery (up to 7·0 per cent). This suggests that aggressive colorectal cancers may have already seeded in the liver and other organs, and that their aggressiveness is maintained after hepatectomy[32](#bjs5100-bib-0032){ref-type="ref"}. This might account for high rates of early recurrence[25](#bjs5100-bib-0025){ref-type="ref"}. This is supported by the observation that slow‐growing CRLMs showed a peak HR late after surgery, usually at 1--2 years. Considering OS, the peak HR for death was advanced by about 1 year for fast‐growing tumours with respect to the recurrence peak, and by about 2 years for more indolent tumours. After this time point, the recurrence HR for faster‐growing tumours returned to a level similar (2·2 per cent) to that of less aggressive tumours (1·9 per cent), although the risk of death remained higher.

The ability to achieve an R0 resection clearly affected RFS. Almost all authors agree that R1 resection is associated with a higher local recurrence risk[9](#bjs5100-bib-0009){ref-type="ref"} [10](#bjs5100-bib-0010){ref-type="ref"}, [33](#bjs5100-bib-0033){ref-type="ref"} [34](#bjs5100-bib-0034){ref-type="ref"}, but this cannot be the sole cause of intrahepatic recurrence. R1 resection may also indicate more diffuse intrahepatic disease, which in turn leads to a more demanding surgical procedure and a lower likelihood of obtaining an R0 resection[35](#bjs5100-bib-0035){ref-type="ref"}. This latter contention is supported by the present results. If an R1 margin was simply due to surgical failure, the HR for recurrence should be high early after surgery and then decrease over time. Instead, it remained consistently above that for R0 margins, suggesting that an R1 margin reflects a more advanced tumour burden with higher metastatic potential over the entire postoperative time period.

The present study has limitations. First, only patients with metachronous disease were considered. Estimation of tumour doubling times in patients with synchronous metastases would provide a more comprehensive picture. The second limitation relates to the reliability of the doubling time estimate. The literature measuring CRLM doubling time is more than 10 years old and, with modern treatments, comparability over such a long time interval may not be valid[19](#bjs5100-bib-0019){ref-type="ref"}, [20](#bjs5100-bib-0020){ref-type="ref"}, [21](#bjs5100-bib-0021){ref-type="ref"}, [22](#bjs5100-bib-0022){ref-type="ref"}, [23](#bjs5100-bib-0023){ref-type="ref"}. Despite this, the present mathematical model has been built on a sound scientific rationale[11](#bjs5100-bib-0011){ref-type="ref"}, [12](#bjs5100-bib-0012){ref-type="ref"}, [13](#bjs5100-bib-0013){ref-type="ref"}, and findings in the cohort not receiving chemotherapy after primary colorectal cancer resection were in keeping with observed doubling time values in earlier cohorts[19](#bjs5100-bib-0019){ref-type="ref"}, [20](#bjs5100-bib-0020){ref-type="ref"}, [21](#bjs5100-bib-0021){ref-type="ref"}, [22](#bjs5100-bib-0022){ref-type="ref"}, [23](#bjs5100-bib-0023){ref-type="ref"}.

The present study has provided a comprehensive estimation of CRLM growth rates in patients with metachronous liver involvement. It would seem reasonable to explore this further in patients with synchronous metastases and to see how doubling time is affected by different chemotherapy regimens.
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